Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles

doi:10.1021/acs.nanolett.8b03439

	Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles
	Li, Ruixiang 2,3; He, Yuwei 2; Zhu, Ying 4; Jiang, Lixian 3; Zhang, Shuya 2; Qin, Jing 2; Wu, Qian 5; Dai, Wentao 5; Shen, Shun 2; Pang, Zhiqing 2
刊名	Nano Letters
	2018
ISSN号	15306984
DOI	10.1021/acs.nanolett.8b03439
文献子类	Article
英文摘要	The targeted delivery of therapeutics to sites of rheumatoid arthritis (RA) has been a long-standing challenge. Inspired by the intrinsic inflammation-targeting capacity of macrophages, a macrophage-derived microvesicle (MMV)-coated nanoparticle (MNP) was developed for targeting RA. The MMV was efficiently produced through a novel method. Cytochalasin B (CB) was applied to relax the interaction between the cytoskeleton and membrane of macrophages, thus stimulating MMV secretion. The proteomic profile of the MMV was analyzed by iTRAQ (isobaric tags for relative and absolute quantitation). The MMV membrane proteins were similar to those of macrophages, indicating that the MMV could exhibit bioactivity similar to that of RA-targeting macrophages. A poly(lactic-co-glycolic acid) (PLGA) nanoparticle was subsequently coated with MMV, and the inflammation-mediated targeting capacity of the MNP was evaluated both in vitro and in vivo. The in vitro binding of MNP to inflamed HUVECs was significantly stronger than that of the red blood cell membrane-coated nanoparticle (RNP). Compared with bare NP and RNP, MNP showed a significantly enhanced targeting effect in vivo in a collagen-induced arthritis (CIA) mouse model. The targeting mechanism was subsequently revealed according to the proteomic analysis, indicating that Mac-1 and CD44 contributed to the outstanding targeting effect of the MNP. A model drug, tacrolimus, was encapsulated in MNP (T-RNP) and significantly suppressed the progression of RA in mice. The present study demonstrates MMV as a promising and rich material, with which to mimic macrophages, and demonstrates that MNP is an efficient biomimetic vehicle for RA targeting and treatment.
语种	英语
出版者	American Chemical Society
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/266962]
专题	中国科学院上海药物研究所
通讯作者	Pang, Zhiqing
作者单位	1.Institute of Materia Medica, Academy of Integrative Medicine, Fudan University, Shanghai; 201203, China 2.Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai; 201203, China; 3.Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai; 201203, China; 4.Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong; 510405, China; 5.Shanghai Center for Bioinformation Technology, Shanghai Industrial Technology Institute, Shanghai; 201203, China;
推荐引用方式 GB/T 7714	Li, Ruixiang,He, Yuwei,Zhu, Ying,et al. Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles[J]. Nano Letters,2018.
APA	Li, Ruixiang.,He, Yuwei.,Zhu, Ying.,Jiang, Lixian.,Zhang, Shuya.,...&Wang, Jianxin.(2018).Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles.Nano Letters.
MLA	Li, Ruixiang,et al."Route to Rheumatoid Arthritis by Macrophage-Derived Microvesicle-Coated Nanoparticles".Nano Letters (2018).